Drugs drugs everywhere, can you access ones that work? Kirstin Spencer

Here at METUPUK, we know drug access is a big issue for all metastatic breast cancer patients. There have been huge leaps and bounds made in terms of research, knowledge

PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer

METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline